Developer docs
API playgroundTry for free, no card

Search company profiles

Tactogen

Full company profile

uuid00087nd

Namestring
Tactogen
Legal namestring
Tactogen Inc
Websiteurl
tactogen.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Tactogen Inc is a Palo Alto-based public benefit corporation founded in 2020 that develops novel small-molecule entactogen medicines for mental health conditions including posttraumatic stress disorder (PTSD), anxiety, depression, and stress-related disorders. The company's pipeline targets known limitations of MDMA — transient anxiety, sedation, impairment, hypertension, and diminished response on repeat dosing — by engineering new chemical entities across four scaffold families: benzofuran-based MDMA analogs (including non-racemic 5-MAPB, 6-MAPB, and novel alpha-ethyl and beta-keto derivatives), benzothiophenes, tryptamines, and indolizines. Its lead composition-of-matter IP is U.S. Patent 11767305, granted September 2023, which the company reports is the first U.S. patent for novel psychoactive MDMA derivatives.

The company's discovery workflow combines machine learning and targeted assays to prioritize candidate molecules, with preclinical validation conducted through research collaborations with the National Institutes of Health (serotonin release and reuptake studies) and Western Michigan University (drug discrimination studies). The company has filed over a dozen patent applications covering molecules, drug combinations, treatment methods, and pharmaceutical preparations. Tactogen maintains a public-benefit governance stance and has engaged in regulatory advocacy, including a successful 2022 coalition effort that led the DEA to withdraw a proposed ban on five tryptamines.

Tactogen is pre-revenue with no commercialized products, pricing, or distribution channels. The company has raised $6.3 million since 2020 from undisclosed investors and, in November 2022, launched a Community Stakeholder Initiative via Wefunder under SEC Regulation CF — a non-traditional funding channel enabling non-accredited public participation, led by MacArthur Fellow Dr. Victoria Hale. Management has stated an intent to raise over $200 million over the next decade to advance the first candidate to market. The company employs 1–10 people, is led by CEO Matthew Baggott, PhD (a leading MDMA neuropharmacologist) and COO Luke Pustejovsky, and focuses its commercial ambitions on the U.S. pharmaceutical market.

Short descriptiontext

Tactogen is a Palo Alto-based public benefit corporation founded in 2020 that develops novel small-molecule entactogen medicines — including benzofuran-based MDMA derivatives, benzothiophenes, tryptamines, and indolizines — targeting PTSD, anxiety, depression, and stress-related disorders. It is a pre-revenue, 1–10 employee biotech using machine learning-driven discovery.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
psychedelic pharmaceuticals, entactogen drug discovery, MDMA derivative therapeutics, mental health medicines, small molecule neuropharmacology
Industry1 code
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Psychedelic Pharmaceuticals
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Tactogen is an early-stage drug discovery company developing novel entactogen medicines. The company anticipates generating revenue through FDA-approved pharmaceutical products once clinical trials are completed. As a public benefit corporation, they plan to raise over $200 million over the next decade to bring their first product to market.

tactogen.com
2Community Stakeholder Initiative (Equity Crowdfunding)
TypeLicensing Royalties
Description

The company launched a community stakeholder initiative via Wefunder, enabling the public to purchase equity stakes. This uses SEC Regulation CF allowing non-accredited individuals to invest as little as $100 into private companies. Funds are used to further study Tactogen's molecules for clinical trials.

tactogen.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Tactogen is a public benefit biopharma company that discovers and develops novel small molecule entactogen medicines for mental health applications. Its core offering is a pipeline of proprietary chemical entities, including benzofuran-based MDMA derivatives, benzothiophenes, tryptamines, and indolizines, designed to treat PTSD, anxiety, depression, and stress-related disorders while minimizing the side effects associated with MDMA. The company uses machine learning and targeted assays to identify and advance drug candidates through preclinical research in collaboration with academic and government partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Novel MDMA derivatives minimize unwanted effects while retaining therapeutic benefits
+1 more record
Product overview1 text field

Tactogen is a public benefit corporation developing a next generation of mental wellness medicines. The company operates as a pharmatech company that develops novel small molecule entactogens — pharmacological agents that increase self-compassion and acceptance — for mental health conditions including anxiety, depression, PTSD, and stress-related disorders. The product portfolio includes novel MDMA derivatives (benzofurans), benzothiophenes, tryptamines, and indolizines. Tactogen uses machine learning and targeted assays to identify promising medicines and evaluates therapeutic potential through academic partnerships and contract research organizations. The company has filed over a dozen patent applications covering molecules, drug combinations, treatment methods, and pharmaceutical preparations as of mid-2025.

Product and service4 records
1Novel MDMA Derivatives (Benzofuran Entactogens)
CategoryEntactogen small molecule pharmaceuticals (benzofuran class)
Description

Proprietary benzofuran-based MDMA analog compounds (non-racemic mixtures of 5-MAPB, 6-MAPB, and previously unexplored alpha-ethyl and beta-keto derivatives) designed to retain MDMA's therapeutic emotional effects while minimizing anxiety, sedation, impairment, and hypertension. The benzofuran structure replaces one oxygen of MDMA with carbon, increasing metabolic resistance and reducing potentially toxic metabolites, and is being developed for prescription mental wellness use in PTSD, anxiety, depression, and stress-related disorders.

2Benzothiophene Entactogens
CategoryEntactogen small molecule pharmaceuticals (benzothiophene class)
Description

Novel benzothiophene-based entactogen compounds developed as part of Tactogen's chemical library for mental health applications, covered by published PCT patent applications covering the compounds themselves, drug combinations, treatment methods, and pharmaceutical preparations.

3Tryptamine Compounds
CategoryEntactogen small molecule pharmaceuticals (tryptamine class)
Description

Novel tryptamine-based chemical entities, including derivatives beyond those covered by existing third-party patents, developed as part of Tactogen's entactogen drug discovery pipeline for mental wellness indications.

4Indolizine Compounds
CategoryEntactogen small molecule pharmaceuticals (indolizine class)
Description

Novel indolizine-based chemical entities developed as part of Tactogen's entactogen drug discovery program for mental health applications, covered by published PCT patent applications covering the compounds, drug combinations, treatment methods, and pharmaceutical preparations.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pennsylvania-based company developing psychedelic therapeutics for mental health conditions. Collaborated with Tactogen on formal opposition to DEA's proposed tryptamine ban. Represented together by Calyx Law and Yetter Coleman LLP.

2Calyx Law
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

San Francisco-based legal representation for Tactogen's regulatory and patent matters.

tactogen.com
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Houston-based legal counsel representing Tactogen in regulatory matters including opposition to DEA tryptamine ban proposal.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Conducts preclinical research on serotonin release and reuptake with Tactogen's molecules.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Conducts preclinical drug discrimination studies with Tactogen's molecules.

6Hamilton Morris
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Renowned pharmacologist who interviewed Tactogen CEO Matthew Baggott on his podcast. Contributed scientific evidence supporting coalition opposing DEA's tryptamine ban proposal.

tactogen.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partner who assembled compelling scientific evidence for coalition opposing DEA's tryptamine ban.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Compass Pathways is a clinical-stage biotechnology company developing psilocybin therapy for treatment-resistant depression, currently in late-stage clinical trials. Comparable as a well-capitalized psychedelic therapeutics company pursuing FDA-regulated psychedelic medicines for mental health, with similar go-to-market challenges around Schedule I compounds.

TypeDirect peer
Description

GH Research is a clinical-stage biopharmaceutical company developing novel serotonergic therapies (including 5-MeO-DMT) for psychiatric and neurological disorders. Comparable as a small-molecule psychedelic therapeutics developer with a focused pipeline targeting treatment-resistant depression.

TypeDirect peer
Description

MAPS PBC (the public benefit corporation affiliated with the Multidisciplinary Association for Psychedelic Studies) is developing MDMA-assisted therapy for PTSD, currently in Phase 3 trials. Most directly comparable to Tactogen as both target MDMA-derived medicines for mental health conditions, though MAPS PBC is significantly more clinically advanced.

4Journey Colab
TypeDirect peer
Description

Journey Colab is developing psychedelic-assisted therapies for mental health conditions including addiction. Comparable as a small psychedelic therapeutics developer with a mission-driven, community-focused approach similar to Tactogen's public benefit orientation - and explicitly co-paneled with Tactogen at MIT Future of Healthcare 2021.

TypeDirect peer
Description

Cybin Inc. is a clinical-stage biopharmaceutical company developing psychedelic-based therapeutics for mental health conditions including depression and anxiety. Comparable as a small-molecule psychedelic therapeutics developer with multiple programs in clinical development.

TypeDirect peer
Description

Usona Institute is a non-profit medical research organization conducting psilocybin clinical trials for major depressive disorder. Comparable as a psychedelic therapeutics developer focused on mental health applications, with a public-benefit-aligned structure similar to Tactogen's PBC status.

TypeDirect peer
Description

Eleusis is a clinical-stage company exploring the therapeutic potential of psychedelics for mental health and inflammatory conditions. Comparable as a small-molecule psychedelic therapeutics developer operating in adjacent therapeutic areas with similar discovery-stage profile.

8MindMed
TypeDirect peer
Description

Mind Medicine (MindMed) is a clinical-stage psychedelic medicine biotech developing novel psychedelic-derived treatments (including LSD analog and MDMA-inspired programs) for mental health. Comparable as a small-molecule psychedelic therapeutics developer with multiple programs in clinical development.

9Atai Life Sciences
TypeDirect peer
Description

Atai Life Sciences is a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for mental health conditions. Comparable as a platform-approach psychedelic therapeutics developer with multiple programs and a significantly larger capital base.

TypeDirect peer
Description

Mindstate Design Labs is a Pennsylvania-based company developing psychedelic therapeutics for mental health conditions. Direct peer and explicit partner of Tactogen on regulatory matters, including the joint opposition to DEA's proposed tryptamine ban - indicating a closely aligned mission and operational profile.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tactogen

Psychedelic Pharmaceuticalstactogen.com

Tactogen is a Palo Alto-based public benefit corporation founded in 2020 that develops novel small-molecule entactogen medicines — including benzofuran-based MDMA derivatives, benzothiophenes, tryptamines, and indolizines — targeting PTSD, anxiety, depression, and stress-related disorders. It is a pre-revenue, 1–10 employee biotech using machine learning-driven discovery.

What Tactogen does

Tactogen Inc is a Palo Alto-based public benefit corporation founded in 2020 that develops novel small-molecule entactogen medicines for mental health conditions including posttraumatic stress disorder (PTSD), anxiety, depression, and stress-related disorders. The company's pipeline targets known limitations of MDMA — transient anxiety, sedation, impairment, hypertension, and diminished response on repeat dosing — by engineering new chemical entities across four scaffold families: benzofuran-based MDMA analogs (including non-racemic 5-MAPB, 6-MAPB, and novel alpha-ethyl and beta-keto derivatives), benzothiophenes, tryptamines, and indolizines. Its lead composition-of-matter IP is U.S. Patent 11767305, granted September 2023, which the company reports is the first U.S. patent for novel psychoactive MDMA derivatives.

The company's discovery workflow combines machine learning and targeted assays to prioritize candidate molecules, with preclinical validation conducted through research collaborations with the National Institutes of Health (serotonin release and reuptake studies) and Western Michigan University (drug discrimination studies). The company has filed over a dozen patent applications covering molecules, drug combinations, treatment methods, and pharmaceutical preparations. Tactogen maintains a public-benefit governance stance and has engaged in regulatory advocacy, including a successful 2022 coalition effort that led the DEA to withdraw a proposed ban on five tryptamines.

Tactogen is pre-revenue with no commercialized products, pricing, or distribution channels. The company has raised $6.3 million since 2020 from undisclosed investors and, in November 2022, launched a Community Stakeholder Initiative via Wefunder under SEC Regulation CF — a non-traditional funding channel enabling non-accredited public participation, led by MacArthur Fellow Dr. Victoria Hale. Management has stated an intent to raise over $200 million over the next decade to advance the first candidate to market. The company employs 1–10 people, is led by CEO Matthew Baggott, PhD (a leading MDMA neuropharmacologist) and COO Luke Pustejovsky, and focuses its commercial ambitions on the U.S. pharmaceutical market.

Tactogen firmographics

Firmographics
Name
Tactogen
Legal name
Tactogen Inc
Website
https://tactogen.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Tactogen is a Palo Alto-based public benefit corporation founded in 2020 that develops novel small-molecule entactogen medicines — including benzofuran-based MDMA derivatives, benzothiophenes, tryptamines, and indolizines — targeting PTSD, anxiety, depression, and stress-related disorders. It is a pre-revenue, 1–10 employee biotech using machine learning-driven discovery.
Ownership category
akta.pro rank

Tactogen industry classification

Industry
Product category
Psychedelic Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Psychedelic pharmaceuticals
  • Entactogen drug discovery
  • MDMA derivative therapeutics
  • Mental health medicines
  • Small molecule neuropharmacology

Where Tactogen is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Tactogen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Revenue: Tactogen is an early-stage drug discovery company developing novel entactogen medicines. The company anticipates generating revenue through FDA-approved pharmaceutical products once clinical trials are completed. As a public benefit corporation, they plan to raise over $200 million over the next decade to bring their first product to market.
  2. Community Stakeholder Initiative (Equity Crowdfunding): The company launched a community stakeholder initiative via Wefunder, enabling the public to purchase equity stakes. This uses SEC Regulation CF allowing non-accredited individuals to invest as little as $100 into private companies. Funds are used to further study Tactogen's molecules for clinical trials.

Go-to-market motion2 records

Marketing channels4 records

Tactogen product offering

Product offering

Core offering

Tactogen is a public benefit biopharma company that discovers and develops novel small molecule entactogen medicines for mental health applications. Its core offering is a pipeline of proprietary chemical entities, including benzofuran-based MDMA derivatives, benzothiophenes, tryptamines, and indolizines, designed to treat PTSD, anxiety, depression, and stress-related disorders while minimizing the side effects associated with MDMA. The company uses machine learning and targeted assays to identify and advance drug candidates through preclinical research in collaboration with academic and government partners.

Product overview

Tactogen is a public benefit corporation developing a next generation of mental wellness medicines. The company operates as a pharmatech company that develops novel small molecule entactogens — pharmacological agents that increase self-compassion and acceptance — for mental health conditions including anxiety, depression, PTSD, and stress-related disorders. The product portfolio includes novel MDMA derivatives (benzofurans), benzothiophenes, tryptamines, and indolizines. Tactogen uses machine learning and targeted assays to identify promising medicines and evaluates therapeutic potential through academic partnerships and contract research organizations. The company has filed over a dozen patent applications covering molecules, drug combinations, treatment methods, and pharmaceutical preparations as of mid-2025.

Differentiator

Problem solved

Functional benefit

Products and services

  • Novel MDMA Derivatives (Benzofuran Entactogens) Proprietary benzofuran-based MDMA analog compounds (non-racemic mixtures of 5-MAPB, 6-MAPB, and previously unexplored alpha-ethyl and beta-keto derivatives) designed to retain MDMA's therapeutic emotional effects while minimizing anxiety, sedation, impairment, and hypertension. The benzofuran structure replaces one oxygen of MDMA with carbon, increasing metabolic resistance and reducing potentially toxic metabolites, and is being developed for prescription mental wellness use in PTSD, anxiety, depression, and stress-related disorders.
  • Benzothiophene Entactogens Novel benzothiophene-based entactogen compounds developed as part of Tactogen's chemical library for mental health applications, covered by published PCT patent applications covering the compounds themselves, drug combinations, treatment methods, and pharmaceutical preparations.
  • Tryptamine Compounds Novel tryptamine-based chemical entities, including derivatives beyond those covered by existing third-party patents, developed as part of Tactogen's entactogen drug discovery pipeline for mental wellness indications.
  • Indolizine Compounds Novel indolizine-based chemical entities developed as part of Tactogen's entactogen drug discovery program for mental health applications, covered by published PCT patent applications covering the compounds, drug combinations, treatment methods, and pharmaceutical preparations.

Quantifiable outcome

  • Novel MDMA derivatives minimize unwanted effects while retaining therapeutic benefits
  • +1 more outcomes

Companies that use Tactogen

Customer profile

Segments2 records

Ideal customer profiles2 records

Tactogen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Tactogen partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Mindstate Design LabscoreStrategic or Co-development PartnerPennsylvania-based company developing psychedelic therapeutics for mental health conditions. Collaborated with Tactogen on formal opposition to DEA's proposed tryptamine ban. Represented together by Calyx Law and Yetter Coleman LLP.
  • Calyx LawminorImplementation/ SI/ Consulting PartnerSan Francisco-based legal representation for Tactogen's regulatory and patent matters.
  • Yetter Coleman LLPminorImplementation/ SI/ Consulting PartnerHouston-based legal counsel representing Tactogen in regulatory matters including opposition to DEA tryptamine ban proposal.
  • National Institutes of Health (NIH)coreStrategic or Co-development PartnerConducts preclinical research on serotonin release and reuptake with Tactogen's molecules.
  • Western Michigan UniversitycoreStrategic or Co-development PartnerConducts preclinical drug discrimination studies with Tactogen's molecules.
  • Hamilton MorrisminorStrategic or Co-development PartnerRenowned pharmacologist who interviewed Tactogen CEO Matthew Baggott on his podcast. Contributed scientific evidence supporting coalition opposing DEA's tryptamine ban proposal.
  • St. Joseph's University (Jason Wallach)minorStrategic or Co-development PartnerAcademic partner who assembled compelling scientific evidence for coalition opposing DEA's tryptamine ban.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Tactogen competitors and assessment

Company assessment

Direct peers

  • Compass Pathways: Compass Pathways is a clinical-stage biotechnology company developing psilocybin therapy for treatment-resistant depression, currently in late-stage clinical trials. Comparable as a well-capitalized psychedelic therapeutics company pursuing FDA-regulated psychedelic medicines for mental health, with similar go-to-market challenges around Schedule I compounds.
  • GH Research: GH Research is a clinical-stage biopharmaceutical company developing novel serotonergic therapies (including 5-MeO-DMT) for psychiatric and neurological disorders. Comparable as a small-molecule psychedelic therapeutics developer with a focused pipeline targeting treatment-resistant depression.
  • MAPS PBC: MAPS PBC (the public benefit corporation affiliated with the Multidisciplinary Association for Psychedelic Studies) is developing MDMA-assisted therapy for PTSD, currently in Phase 3 trials. Most directly comparable to Tactogen as both target MDMA-derived medicines for mental health conditions, though MAPS PBC is significantly more clinically advanced.
  • Journey Colab: Journey Colab is developing psychedelic-assisted therapies for mental health conditions including addiction. Comparable as a small psychedelic therapeutics developer with a mission-driven, community-focused approach similar to Tactogen's public benefit orientation - and explicitly co-paneled with Tactogen at MIT Future of Healthcare 2021.
  • Cybin: Cybin Inc. is a clinical-stage biopharmaceutical company developing psychedelic-based therapeutics for mental health conditions including depression and anxiety. Comparable as a small-molecule psychedelic therapeutics developer with multiple programs in clinical development.
  • Usona Institute: Usona Institute is a non-profit medical research organization conducting psilocybin clinical trials for major depressive disorder. Comparable as a psychedelic therapeutics developer focused on mental health applications, with a public-benefit-aligned structure similar to Tactogen's PBC status.
  • Eleusis: Eleusis is a clinical-stage company exploring the therapeutic potential of psychedelics for mental health and inflammatory conditions. Comparable as a small-molecule psychedelic therapeutics developer operating in adjacent therapeutic areas with similar discovery-stage profile.
  • MindMed: Mind Medicine (MindMed) is a clinical-stage psychedelic medicine biotech developing novel psychedelic-derived treatments (including LSD analog and MDMA-inspired programs) for mental health. Comparable as a small-molecule psychedelic therapeutics developer with multiple programs in clinical development.
  • Atai Life Sciences: Atai Life Sciences is a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for mental health conditions. Comparable as a platform-approach psychedelic therapeutics developer with multiple programs and a significantly larger capital base.
  • Mindstate Design Labs: Mindstate Design Labs is a Pennsylvania-based company developing psychedelic therapeutics for mental health conditions. Direct peer and explicit partner of Tactogen on regulatory matters, including the joint opposition to DEA's proposed tryptamine ban - indicating a closely aligned mission and operational profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Tactogen social profiles

Digital presence

Tactogen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tactogen leadership team

Management profile

Number of profiles

Profiles2 records

Tactogen funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tactogen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tactogen

What does Tactogen do?

Tactogen is a public benefit biopharma company that discovers and develops novel small molecule entactogen medicines for mental health applications. Its core offering is a pipeline of proprietary chemical entities, including benzofuran-based MDMA derivatives, benzothiophenes, tryptamines, and indolizines, designed to treat PTSD, anxiety, depression, and stress-related disorders while minimizing the side effects associated with MDMA. The company uses machine learning and targeted assays to identify and advance drug candidates through preclinical research in collaboration with academic and government partners.

Is Tactogen a public or private company?

Tactogen is a private company. It is classified as venture growth investor backed and is currently operating.

When was Tactogen founded?

Tactogen was founded in 2020. It employs 1 to 10 people.

Where is Tactogen based?

Tactogen is headquartered in Palo Alto, United States, in the North America region.

How does Tactogen make money?

Two revenue lines are on record. Pharmaceutical Product Revenue is the primary driver. The others are community Stakeholder Initiative (Equity Crowdfunding).

Who are Tactogen's main competitors?

Direct peers on record are Compass Pathways, GH Research, MAPS PBC, Journey Colab, Cybin, Usona Institute, Eleusis, MindMed, Atai Life Sciences and Mindstate Design Labs.

Does Tactogen have an API?

No public API is recorded for Tactogen.

What industry is Tactogen in?

Tactogen's product category is Psychedelic Pharmaceuticals. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WikipediaMatthew J. Baggott: Difference between revisionsThe article provides a biographical overview of Matthew Baggott, a neuroscientist and co-founder/CEO of Tactogen Inc, detailing his three-decade career in MDMA research and drug development. It highlights Tactogen's mission to create safer, more accessible MDMA-like medicines and mentions its strategic focus on combination therapies, such as pairing MDMA with SSRIs like citalopram for PTSD treatment. The text also references Baggott's academic background at the University of Chicago and UC Berkeley, as well as his previous role at Genentech.BioSpaceMDMA Drug Developers Reprioritize Following Lykos Rejection in PTSDFollowing the FDA's rejection of Lykos Therapeutics' MDMA-assisted therapy for PTSD, several pharmaceutical companies are reprioritizing their psychedelic drug pipelines to address regulatory concerns and safety issues. Competitors such as Tactogen and atai Life Sciences are adjusting their strategies, with Tactogen focusing on novel compounds and atai advancing its specific enantiomer-based candidate EMP-01. The industry is simultaneously navigating FDA guidance on abuse liability while highlighting the significant unmet medical need for PTSD treatments globally.JourneyclinicalSXSW Psychedelics Panel w/ Myriam BarthesJourney Clinical co-founder and COO Myriam Barthes participated in an SXSW panel titled "Beyond the Hype: The Business of Psychedelics 2.0" alongside representatives from UC Berkeley Center for Psychedelics, Palo Santo, and Tactogen. Barthes outlined Journey Clinical's collaborative care model that connects therapists with prescribers to deliver ketamine-assisted psychotherapy, noting the company has grown to 700 therapists on its platform. The panel also covered the broader ecosystem supporting psychedelic therapy practitioners, including community building and professional education partnerships with Fluence.BloombergAre Hallucinogen Look-Alikes Illegal? DEA Delay Creates LimboThe DEA withdrew its bid to schedule five hallucinogenic compounds as Schedule 1 drugs, sending them back to HHS for review. The move delays the decision, leaving companies like Tactogen and Mindstate Labs in regulatory limbo. The outcome could affect research funding and public health risks from designer drugs.PR NewswireLeading U.S.-Based Psychedelic Healthcare VC Fund Launches with $35 Million Raised to Tackle the Growing Global Mental Health CrisisPalo Santo, a U.S.-based psychedelic healthcare venture capital fund, announced its formal launch with $35 million in initial capital raised and an active portfolio of 20 companies. The fund was co-founded in 2020 by Daniel Goldberg, Tim Schlidt, and Tony Eisenberg, and targets early-stage opportunities across biopharma, drug development, digital therapeutics, and tech-enabled healthcare solutions. Notable portfolio investments include atai Life Sciences, Field Trip Health, Tactogen, Eleusis, Bexson Biomedical, and eight other companies focused on treating conditions such as depression, PTSD, anxiety, and addiction using psychedelic-assisted therapies.